Status:
COMPLETED
Enhancing Therapy Adherence Among Metastatic Breast Cancer Patients
Lead Sponsor:
European Institute of Oncology
Collaborating Sponsors:
Pfizer
Conditions:
Metastatic Breast Cancer
Eligibility:
FEMALE
18+ years
Phase:
NA
Brief Summary
Background: Emerging evidence indicates that patients with advanced cancer, such as those with MBC, often exhibit significant levels of nonadherence to oral anticancer treatments. Leveraging of the ma...
Detailed Description
Metastatic breast cancer (MBC) represents an incurable condition wherein pharmacological interventions are directed towards deferring disease progression and alleviating symptoms, thereby extending su...
Eligibility Criteria
Inclusion
- Patients \> 18 years-old;
- Having a metastatic breast cancer diagnosis;
- Taking oral treatment intervention for metastatic breast cancer;
- Patients with internet access and a personal smartphone or tablet;
- Patients who have read and signed the informed consent.
Exclusion
- Presence of primary psychiatric or neurological conditions;
- Patients who refused to sign the informed consent.
Key Trial Info
Start Date :
May 3 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 15 2024
Estimated Enrollment :
94 Patients enrolled
Trial Details
Trial ID
NCT06161181
Start Date
May 3 2023
End Date
May 15 2024
Last Update
October 15 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
European Institute fo Oncology
Milan, MI, Italy, 20141